GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
Phase 2
Recruiting
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT05382312
- Locations
- πΏπ¦
GSK Investigational Site, Cape Town, South Africa
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
Phase 3
Active, not recruiting
- Conditions
- Herpes Zoster
- Interventions
- Biological: HZ/su vaccine
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3038
- Registration Number
- NCT05371080
- Locations
- π¬π§
GSK Investigational Site, Liverpool, United Kingdom
A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT05340257
- Locations
- π§π·
GSK Investigational Site, SΓ£o Paulo, Brazil
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 123
- Registration Number
- NCT05334368
- Locations
- π¬π§
GSK Investigational Site, Leicester, United Kingdom
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
Phase 1
Recruiting
- Conditions
- Hepatitis B
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 84
- Registration Number
- NCT05330455
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 217
- Registration Number
- NCT05305651
- Locations
- π¬π§
GSK Investigational Site, Plymouth, United Kingdom
A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab
Phase 1
Withdrawn
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: Otilimab
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT05304130
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
Phase 1
Active, not recruiting
- Conditions
- Herpes Simplex
- Interventions
- Biological: Non-adjuvanted HSV formulation 1Biological: Non-adjuvanted HSV formulation 2Biological: Non-adjuvanted HSV formulation 3Biological: HSV formulation 1 with adjuvant 1Biological: HSV formulation 2 with adjuvant 1Biological: HSV formulation 3 with adjuvant 1Biological: HSV formulation 1 with adjuvant 2Biological: HSV formulation 2 with adjuvant 2Biological: HSV formulation 3 with adjuvant 2Drug: PlaceboBiological: HSVTI_F1Biological: HSVTI_F2
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 505
- Registration Number
- NCT05298254
- Locations
- π¬π§
GSK Investigational Site, Southampton, United Kingdom
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)
Phase 3
Completed
- Conditions
- Nasal Polyps
- Interventions
- Biological: Depemokimab (GSK3511294)Drug: Placebo
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 264
- Registration Number
- NCT05281523
- Locations
- πΉπ·
GSK Investigational Site, Tekirdag, Turkey
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT05277051
- Locations
- π¬π§
GSK Investigational Site, Sutton, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath